» Articles » PMID: 16368524

Prostate Cancer Epidemiology

Overview
Journal Front Biosci
Specialty Biology
Date 2005 Dec 22
PMID 16368524
Citations 133
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer is the most common non-skin cancer among men in most western populations, and it is the second leading cause of cancer death among U.S. men. Despite its high morbidity, the etiology of prostate cancer remains largely unknown. Advancing age, race, and a family history of prostate cancer are the only established risk factors. Many putative risk factors, including androgens, diet, physical activity, sexual factors, inflammation, and obesity, have been implicated, but their roles in prostate cancer etiology remain unclear. It is estimated that as much as 42% of the risk of prostate cancer may be accounted for by genetic influences, including individual and combined effects of rare, highly penetrant genes, more common weakly penetrant genes, and genes acting in concert with each other. Numerous genetic variants in the androgen biosynthesis/metabolism, carcinogen metabolism, DNA repair, and chronic inflammation pathways, have been explored, but the results are largely inconclusive. The pathogenesis of prostate cancer likely involves interplay between environmental and genetic factors. To unravel these complex relationships, large well-designed interdisciplinary epidemiologic studies are needed. With newly available molecular tools, a new generation of large-scale multidisciplinary population-based studies is beginning to investigate gene-gene and gene-environment interactions. Results of these studies may lead to better detection, treatment, and, ultimately, prevention of prostate cancer.

Citing Articles

Identification and validation of cigarette smoking-related genes in predicting prostate cancer development through bioinformatic analysis and experiments.

Qian D, Wang X, Lv T, Li D, Chen X Discov Oncol. 2024; 15(1):741.

PMID: 39625524 PMC: 11615168. DOI: 10.1007/s12672-024-01645-2.


Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies.

Liu Y, Zhang Q, Huang X Prostate Cancer Prostatic Dis. 2024; 28(1):210-219.

PMID: 39014063 DOI: 10.1038/s41391-024-00871-7.


Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis.

Oyogoa E, Sonpatki M, Brinkerhoff B, Andeen N, Meyer H, Ryan C Curr Oncol. 2024; 31(5):2393-2399.

PMID: 38785459 PMC: 11119923. DOI: 10.3390/curroncol31050178.


Emerging Trends of Nanomedicines in the Management of Prostate Cancer: Perspectives and Potential Applications.

Deshmukh R, Singh V, Harwansh R, Agrawal R, Garg A, Singh S Pharmaceutics. 2024; 16(3).

PMID: 38543191 PMC: 10976144. DOI: 10.3390/pharmaceutics16030297.


Shifting to transperineal prostate biopsy: A narrative review.

Chung Y, Hong S Prostate Int. 2024; 12(1):10-14.

PMID: 38523899 PMC: 10960089. DOI: 10.1016/j.prnil.2023.11.003.